Source: Resumos (e-Book ). Conference titles: International Congress of the Brazilian Genetics Society. Unidade: FMRP
Subjects: GLIOMA, NEOPLASIAS CEREBRAIS, MEDULA ESPINHAL, BARREIRA HEMATO-ENCEFÁLICA
ABNT
BAPTISTELLA, Mariane Minussi et al. Identification of FDA: approved and blood-brain barrierpenetrating drugs for novel therapies in glioblastoma. 2024, Anais.. Ribeirão Preto: Sociedade Brasileira de Genética (SBG), 2024. Disponível em: https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdf. Acesso em: 28 jan. 2026.APA
Baptistella, M. M., Candido, M. F., Pereira, E. A. da S., Panepucci, R. A., Valera, E. T., & Scrideli, C. A. (2024). Identification of FDA: approved and blood-brain barrierpenetrating drugs for novel therapies in glioblastoma. In Resumos (e-Book ). Ribeirão Preto: Sociedade Brasileira de Genética (SBG). Recuperado de https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdfNLM
Baptistella MM, Candido MF, Pereira EA da S, Panepucci RA, Valera ET, Scrideli CA. Identification of FDA: approved and blood-brain barrierpenetrating drugs for novel therapies in glioblastoma [Internet]. Resumos (e-Book ). 2024 ;[citado 2026 jan. 28 ] Available from: https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdfVancouver
Baptistella MM, Candido MF, Pereira EA da S, Panepucci RA, Valera ET, Scrideli CA. Identification of FDA: approved and blood-brain barrierpenetrating drugs for novel therapies in glioblastoma [Internet]. Resumos (e-Book ). 2024 ;[citado 2026 jan. 28 ] Available from: https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdf
